Products Lacking Good Subgroup Data Shouldn’t Be Approved, Patient, Medical Groups Tell FDA
This article was originally published in The Gray Sheet
Executive Summary
FDA should more strongly enforce requirements for adequate demographic subgroup representation in clinical trials for devices and other medical products, participants said at an April 1 meeting on collection and analysis of clinical trial subpopulation data to support product registration.
You may also be interested in...
Meeting Planned By FDA On Collecting Subgroup Data For Product Submissions
The agency plans a public meeting, required by the FDA Safety and Innovation Act, to chart progress on its action plan to improve industry data collection on demographic subgroups for product submissions and labeling for Feb. 29 at its Maryland headquarters.
Clinical Trial Diversity: ‘How Much More Evidence Do We Need To Move Forward?’
FDA seeks research ideas and plans to include demographic subgroup analyses in review templates as some stakeholders call for bolder action to change how companies conduct clinical trials.
Target Women’s Clinics, Keep Recruitment Open To Get More Women Into Trials, FDA Says In Guidance
FDA urges device firms to use a host of strategies to beef up enrollment of women in clinical trials to support device clearances and approvals, including targeting women’s clinics for recruitment efforts and revising enrollment criteria to include more females, in a final sex-specific clinical study guidance released Aug. 22.